Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.

3.26
EUR
0.00
(0.00%)
-0.52EPS
703.45MMarket Cap
Feb 25Next Earn

Total Valuation

EUR

As of September 30, 2026, Aclaris Therapeutics, Inc. carries a market capitalization of 703.45M, placing it among publicly traded companies globally. Its enterprise value stands at 602.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap703.45M
Enterprise Value602.61M

Important Dates

Aclaris Therapeutics, Inc.'s next confirmed earnings release is scheduled for February 25, 2027.

Earnings Date2/25/2027

Share Statistics

As of September 30, 2026, Aclaris Therapeutics, Inc. has 150.83M shares outstanding.

Shares Outstanding150.83M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 112.24, and the price-to-book ratio stands at 4.78.

PS Ratio112.24
PB Ratio4.78
P/TBV Ratio4.78
P/FCF Ratio-9.54
P/OCF Ratio-9.55

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 106.70 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 602.61M versus a market cap of 703.45M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales106.70

Financial Position

As of September 30, 2026, Aclaris Therapeutics, Inc. maintains a current ratio of 5.09, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities.

Current Ratio5.09
Quick Ratio5.09

Financial Efficiency

EUR

Over the twelve months ended September 30, 2026, Aclaris Therapeutics, Inc. posted a negative return on equity (ROE) of -55.51, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -40.66, reflecting losses generated across the asset base. The company generates approximately 77,364.42 in revenue per employee across its workforce of 73.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-55.51
Return on Assets (ROA)-40.66
Revenue Per Employee77,364.42
Employee Count73.00

Stock Price Statistics

EUR

As of the close on November 17, 2026, Aclaris Therapeutics, Inc.'s stock has gained approximately 53.74% over the past 52 weeks. The 50-day moving average sits at 3.83, while the 200-day moving average is 3.97.

52-Week Price Change53.74%
50-Day Moving Average3.83
200-Day Moving Average3.97

Income Statement

EUR

Over the twelve months ended September 30, 2026, Aclaris Therapeutics, Inc. generated 5.65M in revenue and converted that into -70.26M in net income, yielding earnings per share of -0.52. EBITDA reached -79.49M, while operating income came in at -79.77M.

Revenue5.65M
Gross Profit326,451.00
Operating Income-79.77M
Pretax Income-70.26M
Net Income-70.26M
EBITDA-79.49M
EBIT-79.86M
Earnings Per Share (EPS)-0.52

Balance Sheet

EUR

These figures are as of September 30, 2026. Total book value stands at 147.17M, with working capital of 87.36M providing operational flexibility.

Cash & Cash Equivalents100.84M
Net Debt-17.99M
Equity (Book Value)147.17M
Book Value Per Share0.98
Working Capital87.36M

Cash Flow

EUR

Aclaris Therapeutics, Inc. produced -66.36M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -95,288.40 in capital expenditures, free cash flow totaled -66.45M - equivalent to -0.49 per share.

Operating Cash Flow-66.36M
Capital Expenditures-95,288.40
Free Cash Flow-66.45M
FCF Per Share-0.49

Margins

Over the twelve months ended September 30, 2026, Aclaris Therapeutics, Inc. posted a gross margin of 5.78, reflecting its pricing power and cost economics. The operating margin of -1,412.40 and net profit margin of -1,244.09 provide insight into operational efficiency.

Gross Margin5.78
Operating Margin-1,412.40
Pretax Margin-1,244.09
Profit Margin-1,244.09
EBITDA Margin-1,407.55

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -10.48: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -14.28, meaning Aclaris Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-14.28
FCF Yield-10.48

Scores

As of September 30, 2026, Aclaris Therapeutics, Inc. has an Altman Z-Score of 2.24, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.24